Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 2
1(33.3%)
3Total
N/A(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06621264Not ApplicableRecruiting

Exercise Activity to Improve Mobility in Patients With CKD and PAD

Role: collaborator

NCT01140321Phase 2Completed

Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI

Role: collaborator

NCT03149289Completed

Hepatitis C Virus Infection in Patients With Hemoglobinopathies

Role: collaborator

NCT00673491Not ApplicableCompleted

Clinical Pathways for Effective and Appropriate Care

Role: collaborator

All 4 trials loaded